1
|
González-Barca E, Gato L, Esteve A, Sanz‐Pamplona R, Tomás L, Rodriguez M, Martín García‐Sancho A, Córdoba R, Monter A, Bastos M, Bergua Burgues JM, Sayas MJ, Viguria Alegria MC, Sánchez Blanco JJ, Roig M, Luzardo Henriquez HD, Oña R, Cabezudo E, Infante MS, Queizan JA, Blanco Nuñez O, Mozos A, Climent F, Piris MA. CHARACTERIZATION OF THE ONCOGENIC PHENOTYPE IN EXTRANODAL NATURAL KILLER/T‐CELL LYMPHOMA, NASAL TYPE THROUGH GENE EXPRESSION PROFILE. SPANISH LYMPHOMA GROUP GELTAMO. Hematol Oncol 2021. [DOI: 10.1002/hon.139_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- E González-Barca
- Institut Català d’Oncologia Hospital Duran i Reynals, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona, Hematology L’Hospitalet de Llobregat Barcelona Spain
| | - L Gato
- Fundación Jiménez Díaz, CIBERONC, Pathology Madrid Spain
| | - A Esteve
- nsititut Català d'Oncologia, Unit of Biomarkers and Susceptibility, Oncology Data Analytics Program (ODAP) Medical Oncology Department, B‐ARGO Badalona, Badalona Barcelona Spain
| | - R Sanz‐Pamplona
- Catalan Institute of Oncology (ICO), Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL) and CIBERESP, Unit of Biomarkers and Susceptibility Oncology Data Analytics Program (ODAP), L'Hospitalet de Llobregat Barcelona Spain
| | - L Tomás
- Fundación Jiménez Díaz, CIBERONC, Pathology Madrid Spain
| | - M Rodriguez
- Fundación Jiménez Díaz, CIBERONC, Pathology Madrid Spain
| | | | - R Córdoba
- Fundación Jimenez Díaz, Hematology Madrid Spain
| | - A Monter
- Hospital de la Santa Creu i Sant Pau, Hematology Barcelona Spain
| | - M Bastos
- Gregorio Marañón General University Hospital (HGUGM), Hematology Madrid Spain
| | | | - M. J Sayas
- Hospital Universitario Dr Peset, Hematology Valencia Spain
| | | | | | - M Roig
- Hospital La Fe, Hematology Valencia Spain
| | | | - R Oña
- MD Anderson Cancer Center, Hematology Madrid Spain
| | - E Cabezudo
- Insititut Català d'Oncologia, Hospital Moises Broggi, Hematology, San Juan Despí Barcelona Spain
| | - M. S Infante
- Hospital Infanta Leonor, Hematology Madrid Spain
| | - J. A Queizan
- Hospital General de Segovia, Hematology Segovia Spain
| | - O Blanco Nuñez
- Hospital Universitario de Salamanca, IBSAL, Pathology Salamanca Spain
| | - A Mozos
- Hospital de la Santa Creu i Sant Pau, Pathology Barcelona Spain
| | - F Climent
- Hospital Universitario de Bellvitge, Institut d'Investigaciò Biomédica de Bellvitge IDIBELL Pathology, Hospitalet de LLobregat Barcelona Spain
| | - M. A Piris
- Fundación Jiménez Díaz, Pathology Madrid Spain
| |
Collapse
|
2
|
Bastos‐Oreiro M, Gutierrez A, Martín R, Cabero A, Navarro B, Jimenez‐Unieto A, Alonso C, Gonzalez de Villambrosia S, Córdoba R, Perez de Oteyza J, Infante M, Del Campo R, De la Fuente A, Oña R, García Belmonte D, Salar A, Sancho JM. MAINTENANCE THERAPY AFTER R‐BENDAMUSTINE VS R‐CHOP IN FIRST‐LINE TREATMENT OF LOW‐GRADE FOLLICULAR LYMPHOMA: A MULTICENTRE, RETROSPECTIVE GELTAMO STUDY. Hematol Oncol 2021. [DOI: 10.1002/hon.29_2880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - A. Gutierrez
- Hospital Universitario Son Espases Hematology Palma de Mallorca Spain
| | - R. Martín
- Hospital Universitario Gregorio Marañón Hematology Madrid Spain
| | - A. Cabero
- Hospital Clínico Universitario de Salamanca Hematology Salamanca Spain
| | - B. Navarro
- Hospital Universitario Puerta de hierro Hematology Majadahonda Spain
| | | | - C. Alonso
- Hospital Arnau de Villanova Hematology Valencia Spain
| | | | - R. Córdoba
- Hospital Universitario Fundación Jiménez Díaz Hematology Madrid Spain
| | | | | | - R. Del Campo
- Hospital Universitario Son LLatzer Hematology Palma de Mallorca Spain
| | | | - R. Oña
- Hospital MD Anderson Madrid Hematology Madrid Spain
| | | | - A. Salar
- Hospital Universitario del mar Hematology Barcelona Spain
| | - J. M. Sancho
- Hospital Germans Trias i Pujol Hematology Barcelona Spain
| |
Collapse
|
3
|
Meseguer E, Llamas P, Fernández de Velasco J, García A, Echevarria A, Oña R, Rábano J, Tomas JF, García de Yébenes J. [Prothrombotic factors in stroke]. Neurologia 2004; 19:99-105. [PMID: 15088159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023] Open
Abstract
INTRODUCTION Factor V Leiden and prothrombin 20210A polymorphisms are the most common mutations related to deep vein thrombosis, however their relationship with stroke is debated. This paper studies the possible relationship between both entities. MATERIAL AND METHODS A case-control study was conducted during 27 months to study their association. A total of 312 stroke cases were included, 73 were under 60 years. Control group was obtained from blood donors. Factor V Leiden and prothrombin 20210A polymorphism prevalence was studied. Results were analyzed according to the age and the type of stroke (TOAST classification, 1993). RESULTS Factor V Leiden was not related to stroke in the general population (OR: 0.65; 95 % CI: 0.18-2.27). The study according to age did not show any association (younger than 60 years: OR: 1.12; 95 % CI: 0.21-5.90; older than 60 years: OR: 0.50; 95 % CI: 0.11-2.14). However, prothrombin 20210A polymorphism OR in cases under 60 was OR: 2.92; 95 % CI: 0.71-11.92 suggesting a possible association between this mutation and stroke. There was no association in the general population (OR: 2.0; 95 % CI: 0.63-6.29) or in people over 60 (OR: 1.73; 95 % CI: 0.51- 5.83). The analysis according to stroke subtype did not show any association in the distribution of any of the polymorphisms studied. CONCLUSION This study suggests that prothrombin 20210A polymorphism may play a role in stroke under 60 years of age. Factor V Leiden does not seem to be related to stroke.
Collapse
Affiliation(s)
- E Meseguer
- Servicio Neurología, Fundación Jiménez Díaz, Madrid
| | | | | | | | | | | | | | | | | |
Collapse
|